Daily funding roundup - January 8th, 2021

SilviaTerra raised $4.4M; Hipcamp landed $57M; DiCE Molecules secured $80M; Affinivax picks up $226M

SilviaTerra: SilviaTerra is a San Francisco-based forestry company for organizations to exchange carbon offsets. SilviaTerra has raised $4.4 million seed round. Union Square Ventures' climate-tech fund led the round, joined by Scribble Ventures, Gratitude Railroad, Alpha Edison, CoFound Partners and several high-profile individuals, including Salesforce founder Marc Benioff and Pinterest cofounder Ben Silbermann. Read more

Abcuro: Abcuro is a Newton, Ma.-based company focused on autoimmune diseases and cancers. Abcuro has raised $42 million in Series A1 funding. Mass General Brigham Ventures and Sanofi Ventures led the round, joined by Pontifax Venture Capital, Hongsen Investment Group, RA Capital Management, and Samsara BioCapital. Read more 

Hipcamp: Hipcamp is a San Francisco-based company that works with landowners to offer tent camping, RV parks, cabins, treehouses, and glamping—everywhere from national parks to farms. Hipcamp has raised $57 million in Series C funding from Index Ventures and Bond Capital, among others. The deal values the company at more than $300 million, says The Information. Read more 

DiCE Molecules: DiCE Molecules is a South San Francisco, Ca.-based biopharmaceutical company focused on immunology. DiCE Molecules has raised $80 million in Series C funding. RA Capital Management led the round, joined by Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Osage University Partners, Asymmetry Capital Management, Northpond Ventures, Sands Capital, Sanofi Ventures, Alexandria Venture Investments, Altitude Life Science Ventures, and Agent Capital. Read more

LEXEO Therapeutics: LEXEO Therapeutics is a New York-based clinical-stage gene therapy company. LEXEO Therapeutics has raised $85 million in Series A funding led by Longitude Capital and Omega Funds. The company's CEO, Roland Townsend, was previously the president of Pfizer's North American rare disease division. Read more 

Scorpion Therapeutics: Scorpion Therapeutics is a Boston-based precision oncology startup. Scorpion Therapeutics has raised $162 million in Series B funding, including from Boxer Capital, EcoR1 Capital, Omega Funds, and roughly a dozen other backers, including earlier investors Atlas Venture and Abingworth. Read more

Affinivax: Affinivax is a Cambridge, Ma.-based vaccines developer that was seed funded by the Bill and Melinda Gates Foundation. Affinivax raised $226 million in Series C funding. Rock Springs Capital and Foresite Capital co-led the round, joined by T. Rowe Price, Wellington Management, Blackrock, Cormorant, Perceptive Advisors, EcoR1 Capital, Surveyor Capital, Logos Capital and insiders Viking Global Investors, Bain Capital Life Sciences and Ziff Capital Healthcare Ventures. Read more

If you are interested in being included in our funding roundup, submit your press release or blog post about your financing round to kristin@vator.tv. If you want a longer write-up, please do give us a couple of days heads up. If you'd like to be included in our Today's Entrepreneur column, please send me your Vator profile.

Image by Free-Photos from Pixabay